Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

Abstract

Clinical trials of antibodies targeting programmed cell death 1 (PD-1), an inhibitory receptor expressed on activated lymphocytes, or its major ligand, PD-L1, show activity across a broad range of advanced cancers.¹ Antibodies blocking PD-1 or PD-L1 are currently approved by the US Food and Drug Administration for treating multiple individual cancer types in the advanced or metastatic disease setting and for the broad, genetically defined category of microsatellite instability-high tumors.² They are also approved in the adjuvant setting for melanoma and are under investigation in adjuvant and/or neoadjuvant protocols in various tumor types. Anti–PD-L1 treatment is generally well tolerated, with grade 3 to 4 treatment-related adverse events (AEs) observed in approximately 10% to 20% of patients.^3-5